Would you boost a resected axilla if extra-nodal extension is found in a patient with breast cancer?

The data on ECE for breast suggests it increases the risk of recurrence in undissected axilla or supraclav region. We don’t boost ECE region and most of the time don’t even include the dissected axilla with ECE in treatment volume unless the dissection is inadequate.